

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.**

**FOR IMMEDIATE RELEASE**

**21 JUNE 2024**

**Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the Company")**

**Admission to Trading on the London Stock Exchange**

Further to the announcement on 19 June 2024, Oxford Nanopore Technologies plc announces that 11,041,901 ordinary shares have today been admitted to the standard listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange under the ticker 'ONT'.

For further information, please contact:

**Oxford Nanopore Technologies plc**

Investors: [ir@nanoporetech.com](mailto:ir@nanoporetech.com)

Media: [media@nanoporetech.com](mailto:media@nanoporetech.com)

**Teneo (communications adviser to the Company)**

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

[OxfordNanoporeTechnologies@teneo.com](mailto:OxfordNanoporeTechnologies@teneo.com)

**About Oxford Nanopore Technologies plc:**

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

[www.nanoporetech.com](http://www.nanoporetech.com)

**Forward-looking statements**

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ALSEAPKFASSLEEA